CLEARWATER, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 10, 2026 in Snowbird, Utah. To request a meeting with Apyx, investors should contact their BTIG representatives. A ...

Financial Results - Apyx Medical Corporation reported preliminary revenue results for Q4 and the year ended December 31, 2025[5] - The press release detailing these results was issued on January 12, 2026[5] Company Information - The company is listed on the Nasdaq Global Select Market under the trading symbol APYX[3] - Apyx Medical Corporation is incorporated in Delaware and has an Employer Identification Number of 11-2644611[2] Report Details - The report includes a cover page interactive data file as part of its exhibits[8] Management - Matthew Hill serves as the Chief Financial Officer, Secretary, and Treasurer of Apyx Medical Corporation[11]

Core Viewpoint - Apyx Medical Corporation reported preliminary revenue results for Q4 and full year 2025, highlighting strong growth driven by the commercial launch of the AYON Body Contouring System and increased demand in the surgical aesthetics market [1][4]. Preliminary Fourth Quarter 2025 Revenue Summary - Total revenue for Q4 2025 is expected to be in the range of approximately $19.0 to $19.2 million, representing an increase of approximately 34% year-over-year [7]. - Surgical Aesthetics revenue for Q4 2025 is expected to be in the range of approximately $16.6 to $16.8 million, reflecting an increase of approximately 38% year-over-year [7]. - OEM revenue for Q4 2025 is expected to be approximately $2.4 million, indicating an increase of approximately 13% year-over-year [7]. Preliminary Full Year 2025 Revenue Summary - Total revenue for the full year 2025 is expected to be in the range of approximately $52.7 to $52.9 million, representing an increase of approximately 10% year-over-year [7]. - Surgical Aesthetics revenue for the full year 2025 is expected to be in the range of approximately $45.2 to $45.4 million, showing an increase of approximately 17% year-over-year [7]. - OEM revenue for the full year 2025 is expected to be approximately $7.5 million, reflecting a decrease of 21% year-over-year [7]. Industry Context - The commercial launch of AYON has generated immediate momentum, contributing to a strong fourth quarter performance, with a noted increase in aesthetic surgical procedures in the U.S. driven by the adoption of GLP-1 therapies leading to significant patient weight loss [4]. - The company is positioned to capitalize on the positive industry momentum in the surgical aesthetics market [4]. Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion® and the AYON Body Contouring System™ [5]. - The AYON Body Contouring System is an FDA-cleared, surgeon-designed platform that integrates various capabilities for comprehensive body contouring treatments [5]. - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical documents, showcasing the company's commitment to innovation in the cosmetic surgery market [5].

Core Insights - Apyx Medical Corporation has received regulatory approval for the Apyx One console and plans to launch commercial sales in South Korea, with initial orders expected in Q4 2025 [1][3] - The Apyx One console features a 3-in-1 energy system that allows for advanced surgical procedures, including Renuvion technology, and is designed for ease of use with adaptive touch screens and energy quantification [2] - The cosmetic surgery market in South Korea is projected to grow from $1.7 billion in 2024 to over $3.9 billion by 2033, indicating a significant opportunity for Apyx Medical's body contouring technology [3] Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion and the AYON Body Contouring System, which provide controlled heat to tissue for surgical procedures [4] - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple surgical capabilities, enhancing the versatility and precision of body contouring treatments [4]

Core Viewpoint - Apyx Medical Corporation has announced a public offering of 2,762,431 shares of its common stock at a price of $3.62 per share, with the offering expected to close on or about November 19, 2025 [1][2]. Group 1: Offering Details - The offering is underwritten by Lucid Capital Markets, which is acting as the sole book-running manager [2]. - The company has granted the underwriter a 45-day option to purchase an additional 414,365 shares at the public offering price [2]. - The net proceeds from the offering will be used for working capital and general corporate purposes [3]. Group 2: Regulatory and Documentation - The offering is made pursuant to a shelf registration statement filed with the SEC, which was declared effective on December 2, 2022 [3]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [4]. Group 3: Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering products like Renuvion and the AYON Body Contouring System, which provide innovative solutions in cosmetic surgery [6]. - The company’s technologies, including Helium Plasma Platform Technology, are supported by over 90 clinical documents, demonstrating their effectiveness [6]. - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple surgical capabilities, enhancing the treatment options available to surgeons [6].

Core Viewpoint - Apyx Medical Corporation is initiating an underwritten public offering of its common stock, subject to market conditions, with no assurance on the completion or terms of the offering [1]. Group 1: Offering Details - Lucid Capital Markets is the sole book-running manager for the offering [2]. - The offering is made under a shelf registration statement filed with the SEC on November 22, 2022, and declared effective on December 2, 2022 [2]. Group 2: Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering products like Renuvion and the AYON Body Contouring System, which are designed to enhance surgical outcomes [5]. - The Renuvion and J-Plasma technologies provide controlled heat to tissue, supported by over 90 clinical documents [5]. - The AYON Body Contouring System is FDA-cleared and integrates multiple capabilities for comprehensive body contouring treatments [5].

Core Insights - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article emphasizes that users may be blocked from proceeding if an ad-blocker is enabled [1]

Revenue and Sales Performance - Total revenue increased by 12.1%, or approximately $1.4 million, for the three months ended September 30, 2025, compared to the same period in 2024[75]. - Surgical Aesthetics segment sales increased 19.1%, or approximately $1.8 million, for the three months ended September 30, 2025, driven by the commercial launch of AYON and increased sales of single-use handpieces[75]. - OEM segment sales decreased 17.6%, or approximately $0.4 million, for the three months ended September 30, 2025, due to lower sales volume to existing customers[75]. - Surgical Aesthetics sales increased 8.0%, or approximately $2.1 million, for the nine months ended September 30, 2025, compared to the same period in 2024[76]. - OEM segment sales decreased 31.4%, or approximately $2.3 million, for the nine months ended September 30, 2025, due to decreased sales volume to existing customers[76]. Profitability and Margins - Gross profit for the three months ended September 30, 2025, increased 19.3% to $8.3 million, with a gross margin of 64.4% compared to 60.5% for the same period in 2024[78]. - Gross profit for the nine months ended September 30, 2025, increased 3.2% to $21.0 million, with a gross margin of 62.5% compared to 60.2% in the prior year[80]. Cost Management and Expenses - The company reduced its workforce by nearly 25% in November 2024, estimating annualized future cost savings of approximately $4.3 million[69]. - The company plans to reduce annual operating expenses below $40 million in 2025 through various cost-saving measures[69]. - Research and development expenses decreased 38.7% for the nine months ended September 30, 2025, totaling $2.4 million, primarily due to lower compensation and benefits costs[82]. - Professional services expense decreased 14.4% for the nine months ended September 30, 2025, amounting to $4.6 million, driven by reductions in physician and marketing consulting expenses[84]. - Salaries and related expenses decreased 27.5% for the nine months ended September 30, 2025, totaling $9.3 million, due to lower headcount and stock-based compensation[86]. - Selling, general and administrative expenses decreased 20.3% for the nine months ended September 30, 2025, amounting to $11.2 million, primarily due to lower travel and meeting costs[89]. Cash Flow and Financial Position - At September 30, 2025, cash and cash equivalents were approximately $25.1 million, down from $31.7 million at December 31, 2024[93]. - Net cash used in operating activities for the nine months ended September 30, 2025, was approximately $5.5 million, a decrease from $15.5 million in the prior year[94]. - The company had purchase commitments totaling approximately $4.4 million, expected to be purchased within the next twelve months[101]. Compliance and Risk Management - As of September 30, 2025, the company was in compliance with the financial covenants of the Perceptive Credit Agreement, which includes revenue targets for the Surgical Aesthetics segment[98]. - The company has adjusted its accounts receivable allowance due to economic uncertainty in the capital equipment market, particularly in the aesthetic space, resulting in extended credit terms granted to customers[104]. - The company maintains a reserve for uncollectible accounts receivable, analyzing historical bad debt experience and the composition of outstanding receivables[104]. - There are no off-balance sheet arrangements currently in place[106]. - The company has not identified any changes in internal control over financial reporting that materially affect its operations[111]. - The management's disclosure controls and procedures were deemed effective as of September 30, 2025[110]. - There have been no material changes to the risk factors previously described in the Annual Report for the fiscal year ended December 31, 2024[115]. - The company has recorded liabilities for litigation contingencies when a loss is known or considered probable, requiring significant judgment[105]. - The company has not reported any unregistered sales of equity securities or defaults upon senior securities[116][117]. - The company has not disclosed any new products, technologies, market expansions, or acquisitions in the current report[108]. - There are no significant quantitative or qualitative disclosures about market risk applicable to the company[109]. Product Development - The AYON Body Contouring System™ received 510(k) clearance from the FDA on May 13, 2025, and the commercial launch commenced in September 2025[66].

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 increased by 12% to $12.9 million compared to $11.5 million in the same period last year [5][16] - Gross profit for Q3 2025 increased to $8.3 million, with a gross profit margin of 64.4%, up from 60.5% in the prior year [17][19] - Net loss attributable to stockholders decreased to $2 million, or $0.05 per share, compared to $4.7 million, or $0.14 per share in the prior year [19] - Cash used in operating activities decreased to $3.5 million for Q3 2025, down from $4.4 million in the prior year [20] Business Line Data and Key Metrics Changes - Revenue from the surgical aesthetics segment increased by 19% to $11.1 million compared to $9.3 million last year, driven by the commercial launch of the Aon body contouring system [5][16] - OEM revenue decreased by 18% to $1.8 million for Q3 2025, down from $2.2 million in the same period last year, due to reduced sales volumes to existing customers [7][17] Market Data and Key Metrics Changes - Domestic revenue increased by 20% year-over-year to $9.3 million, while international revenue decreased by 4% year-over-year to $3.5 million [17] - The company noted that the medical device industry typically experiences seasonality, with revenue trends generally lowest in the first and third quarters [17] Company Strategy and Development Direction - The company announced a rebranding of its advanced energy segment to "surgical aesthetics" to better align with its mission and the results delivered by its products [5] - The Aon body contouring system is positioned as a groundbreaking solution in the market, integrating multiple functions to enhance surgical outcomes [9][10] - The company is focusing resources on the surgical aesthetics segment, particularly the Aon launch, which is seen as the future of the company [7][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the market's response to the Aon system, highlighting strong pre-sales and initial deliveries [6][14] - The company anticipates continued growth driven by the increasing adoption of GLP-1 medications, which create a demand for body contouring solutions [12][34] - Management updated revenue guidance for 2025 to a range of $50.5 million to $52.5 million, reflecting the strength of the Aon launch [21][22] Other Important Information - The company has successfully reduced operating expenses to $9.1 million for Q3 2025, down from $10.6 million in the prior year, due to cost-cutting measures [18] - Cash and cash equivalents as of September 30, 2025, were $25.1 million, down from $31.7 million as of December 31, 2024 [21] Q&A Session Summary Question: Clarification on generator sales decline - Management explained that the decline in generator sales is due to the integration of existing generators with the new Aon system, which is classified as Aon sales [25][26] Question: Gross margin impact and future expectations - Management refrained from providing specific guidance on gross margins but indicated that the surgical aesthetics business typically has the highest gross margins [27][29] Question: Expected uptake in consumables alongside capital sales - Management noted that new customers adopting Renuvion technology would drive consumable sales, while existing customers may not see significant increases [32] Question: Market demand trends and GLP-1 dynamics - Management confirmed that the market is being disrupted by GLP-1 drugs, with a significant percentage of patients being new to aesthetics, indicating a growing opportunity [34][35] Question: Pipeline growth and implementation - Management acknowledged an increase in guidance due to strong interest in Aon and confirmed that a third party is assisting with installations to meet demand [45][46] Question: International rollout plans for Aon - Management indicated that while the focus is currently on the U.S. market, there are plans to register Aon in various international markets, including Europe and Latin America [48][49]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 increased by 12% to $12.9 million compared to $11.5 million in the same period last year [5][16] - Gross profit for Q3 2025 increased to $8.3 million, with a gross profit margin of 64.4%, up from 60.5% in the prior year [17][19] - Net loss attributable to stockholders decreased to $2 million, or $0.05 per share, compared to $4.7 million, or $0.14 per share in the prior year [19] Business Line Data and Key Metrics Changes - Revenue from the Surgical Aesthetics segment increased by 19% to $11.1 million, driven by the AYON Body Contouring System launch and increased sales of single-use handpieces [5][16] - OEM revenue decreased by 18% to $1.8 million, attributed to reduced sales volumes to existing customers [7][17] Market Data and Key Metrics Changes - Domestic revenue increased by 20% year-over-year to $9.3 million, while international revenue decreased by 4% to $3.5 million [17] - The company noted that the medical device industry typically experiences seasonality, with revenue trends generally lowest in the first and third quarters [17] Company Strategy and Development Direction - The company announced the rebranding of its Advanced Energy segment to Surgical Aesthetics to better align with its mission and product offerings [5] - The focus has shifted towards the Surgical Aesthetics segment, particularly the AYON launch, which is seen as the future of the company [7][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the market's response to AYON, highlighting strong pre-sales and initial deliveries [6][15] - The company anticipates continued growth driven by the increasing adoption of GLP-1 medications, which create a demand for body contouring solutions [12][34] Other Important Information - The company has successfully reduced operating expenses to $9.1 million for Q3 2025, down from $10.6 million in the prior year [18] - Cash used in operating activities decreased to $3.5 million for Q3 2025, compared to $4.4 million in the prior year [19][20] Summary of Q&A Session Question: Clarification on generator sales decline - Management clarified that the decline in generator sales is due to customers integrating existing generators with AYON, rather than purchasing new generators [25][26] Question: Gross margin impact and future guidance - Management refrained from providing specific guidance on gross margins but indicated that the Surgical Aesthetics business typically has the highest gross margins [27][29] Question: Expectations for consumables uptake - Management noted that the greatest driver of consumable sales will come from new customers adopting Renuvion technology [32] Question: Market demand trends and GLP-1 dynamics - Management stated that the market is being disrupted by GLP-1 drugs, with a significant percentage of patients being new to aesthetics [34][35] Question: Growth in single-use handpieces - Management indicated that growth in handpieces is driven by new doctors adopting the technology and higher attach rates for Renuvion [39] Question: Pipeline growth and installation processes - Management confirmed an increase in guidance for Surgical Aesthetics and highlighted the effective management of supply chain and installations [45][46] Question: International rollout of AYON - Management discussed plans for international registration of AYON, with a focus on Europe and other regions in the future [48][49]